Shilpa Biologicals partnered with Orion to co-develop and supply a Nivolumab biosimilar for Europe.

Shilpa Medicare LimitedSHILPAMED · Filed with the exchange

Shilpa will lead development & manufacturing, earning milestone payments and supply revenue from this significant ~$4.1 billion market.

No comments yet. Be the first.

More from Shilpa Medicare Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.